This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bellamy, W. T. Articles by Alberts, D. S. Search for Related Content PubMed PubMed Citation Articles by Bellamy, W. T. Articles by Alberts, D. S.

Verapamil Reversal of Doxorubicin Resistance in Multidrug-resistant Human Myeloma Cells and Association with Drug Accumulation and DNA Damage¹

Department of Medicine and Cancer Pharmacology Program, Arizona Cancer Center, Tucson, Arizona 85724

Verapamil reversed resistance to doxorubicin in a human multiple myeloma cell line selected for multiple drug resistance. The drug-resistant cell line 8226/DOX40 is known to have reduced intracellular drug accumulation associated with the overexpression of P-glycoprotein when compared to the sensitive parent cell line 8226/S. Verapamil alone was minimally cytotoxic in both cell lines, but reversed doxorubicin resistance in a dose-related manner in 8226/DOX40. A similar dose-response relationship was observed for verapamil in increasing net intracellular doxorubicin accumulation. This increased net accumulation was secondary to block of enhanced doxorubicin efflux by verapamil from resistant cells. In contrast, verapamil did not alter initial doxorubicin accumulation over the first 60 s when incubated with resistant cells. Addition of verapamil to the 8226/DOX40 cells enhanced the formation of doxorubicin-induced DNA single strand breaks, double strand breaks, and DNA-protein cross-links. Verapamil had no effect on these lesions in the drug-sensitive cells. In addition, verapamil did not affect chemotherapeutic cytotoxicity or transport in the drug-sensitive cell line. Verapamil appears to reverse doxorubicin resistance in this human myeloma cell line by blocking enhanced drug efflux, leading to increased drug accumulation and enhanced DNA damage.

¹ This work was supported in part by National Cancer Institute Grants CA43043, CA27032, and CA17094.

² 1987–1988 Sterling-Winthrop Pharmacology/Toxicology Fellow.

³ To whom requests for reprints should be addressed, at Cancer Pharmacology Program, Arizona Cancer Center, Tucson, AZ 85724.

Received 3/21/88. Revised 6/14/88. Accepted 8/18/88.

This article has been cited by other articles:

				Y. Zhang, J. P. Bressler, J. Neal, B. Lal, H.-E. C. Bhang, J. Laterra, and M. G. Pomper ABCG2/BCRP Expression Modulates D-Luciferin Based Bioluminescence Imaging Cancer Res., October 1, 2007; 67(19): 9389 - 9397. [Abstract] [Full Text] [PDF]

				L. Catley, E. Weisberg, T. Kiziltepe, Y.-T. Tai, T. Hideshima, P. Neri, P. Tassone, P. Atadja, D. Chauhan, N. C. Munshi, et al. Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood, November 15, 2006; 108(10): 3441 - 3449. [Abstract] [Full Text] [PDF]